Skip Navigation


NDT Advance Access originally published online on January 4, 2008
Nephrology Dialysis Transplantation 2008 23(3):783-785; doi:10.1093/ndt/gfm924
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/3/783    most recent
gfm924v3
gfm924v2
gfm924v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zoccali, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zoccali, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Endothelial dysfunction in CKD: a new player in town?

Carmine Zoccali

Nephrology, Dialysis, Transplantation and Hypertension Unit, CNR-IBIM, Ospedali Riuniti, Reggio Cal, Italy

Carmine Zoccali, Unità Operativa Nefrologia, Dialisi e Trapianto Ospedali Riuniti, 89124 Reggio Cal, Italy. E-mail: carmine.zoccali@tin.it

Keywords: adipokines; adiponectin; chronic kidney disease; endothelial dysfunction; Visfatin

The first 150 words of the full text of this article appear below.

Endothelial dysfunction represents an obligatory, prodromal phase in the atherosclerosis process. Initially identified and thoroughly investigated in bench experiments, endothelial dysfunction has now progressed to a full-fledged outcome measure in clinical studies [1]. Endothelial function may be tested by two approaches [2]. The first is functional in nature and is based on the forearm haemodynamic response to acetylcholine (a pharmacological stimulus impinging upon the enzyme NO synthase) or to ischaemia [flow-mediated vasodilatation –(FMD) a physiological stimulus to the same enzyme]. The second approach rests on the measurement of the plasma concentration of specific biomarkers, i.e. a series of compounds, synthesized within the endothelium and that are released into the systemic circulation when endothelial integrity is hampered by noxious factors. The intercellular (ICAM) and vascular (VCAM) adhesion molecules, endothelial selectin (E-Selectin) and von Willebrand Factor (vWF) are currently held as the most reliable biomarkers of endothelial dysfunction/damage. . . . [Full Text of this Article]



   Endothelial dysfunction in CKD
 
The adipose tissue as a prime-time player in endothelial dysfunction
Adiponectin, Visfatin and endothelial function in CKD

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?